# 1 Methodological Challenges using Routine

- <sup>2</sup> Clinical Care Data for Real-World Evidence: a
- 3 Rapid Review utilizing a systematic literature
- 4 search and focus group discussion
- 5

Michelle Pfaffenlehner<sup>1,2\*</sup>, Max Behrens<sup>1,2</sup>, Daniela Zöller<sup>1,2</sup>, Kathrin Ungethüm<sup>3,4</sup>, Kai 6 Günther<sup>3,4</sup>, Viktoria Rücker<sup>4</sup>, Jens-Peter Reese<sup>3-6</sup>, Peter Heuschmann<sup>3,4,6</sup>, Miriam 7 Kesselmeier<sup>7</sup>, Flavia Remo<sup>7</sup>, André Scherag<sup>7</sup>, Harald Binder<sup>1,2</sup>, Nadine Binder<sup>8,2</sup> – for 8 9 the EVA4MII project 10 <sup>1</sup> Institute of Medical Biometry and Statistics, Faculty of Medicine and Medical Centre – University of 11 Freiburg, Freiburg, Germany <sup>2</sup> Freiburg Centre for Data Analysis and Modelling, University of Freiburg, Freiburg, Germany 12 <sup>3</sup> Institute for Medical Data Sciences, University Hospital Würzburg, Würzburg, Germany 13 <sup>4</sup> Institute for Clinical Epidemiology and Biometry, University Würzburg, Würzburg, Germany 14 <sup>5</sup> Faculty of Health Sciences, THM Technische Hochschule Mittelhessen, University of Applied 15 16 Sciences <sup>6</sup> Clinical Trial Centre, University Hospital Würzburg, Würzburg, Germany 17 18 <sup>7</sup> Institute of Medical Statistics, Computer and Data Sciences, Friedrich Schiller University & Jena 19 University Hospital, Jena, Germany <sup>8</sup> Institute of General Practice/Family Medicine, Faculty of Medicine and Medical Centre - University of 20 21 Freiburg, Freiburg, Germany 22 \*corresponding author: michelle.pfaffenlehner@uniklinik-freiburg.de

It is made available under a CC-BY 4.0 International license .

### 23 Abstract

#### 24 Background

25 The integration of real-world evidence (RWE) from real-world data (RWD) in clinical 26 research is crucial for bridging the gap between clinical trial results and real-world 27 outcomes. Analyzing routinely collected data to generate clinical evidence faces 28 methodological concerns like confounding and bias, similar to prospectively 29 documented observational studies. This study focuses on additional limitations 30 frequently reported in the literature, providing an overview of the challenges and 31 biases inherent to analyzing routine clinical care data, including health claims data 32 (hereafter: routine data).

#### 33 Methods

34 We conducted a literature search on routine data studies in four high-impact journals 35 based on the Journal Citation Reports (JCR) category "Medicine, General & Internal" 36 as of 2022 and three oncology journals, covering articles published from January 37 2018 to October 2023. Articles were screened and categorized into three scenarios 38 based on their potential to provide meaningful RWE: (1) Burden of Disease, (2) 39 Safety and Risk Group Analysis, and (3) Treatment Comparison. Limitations of this 40 type of data cited in the discussion sections were extracted and classified according 41 to different bias types: main bias categories in non-randomized studies (information 42 bias, reporting bias, selection bias, confounding) and additional routine data-specific 43 challenges (i.e., operationalization, coding, follow-up, missing data, validation, and 44 data quality). These classifications were then ranked by relevance in a focus group 45 meeting of methodological experts. The search was pre-specified and registered in 46 PROSPERO (CRD42023477616).

It is made available under a CC-BY 4.0 International license .

#### 47 Results

In October 2023, 227 articles were identified, 69 were assessed for eligibility, and 39 were included in the review: 11 on the burden of disease, 17 on safety and risk group analysis, and 11 on treatment comparison. Besides typical biases in observational studies, we identified additional challenges specific to RWE frequently mentioned in the discussion sections. The focus group had varied opinions on the limitations of Safety and Risk Group Analysis and Treatment Comparison but agreed on the essential limitations for the Burden of Disease category.

#### 55 Conclusion

This review provides a comprehensive overview of potential limitations and biases in analyzing routine data reported in recent high-impact journals. We highlighted key challenges that have high potential to impact analysis results, emphasizing the need for thorough consideration and discussion for meaningful inferences.

Keywords: rapid review, limitation, bias, routine clinical care data, real-world
 evidence, EHR

### 63 Background

Real-world evidence (RWE) derived from real-world data (RWD) becomes increasingly important to support clinical evidence. The growing availability of such data opens up new research opportunities to improve our understanding of clinical practice. A recent definition of real-world data includes data sources such as routine clinical care data, frequently called electronic health records (EHRs), disease-specific registries, administrative data, such as claims data or death registries, and data collected through personal devices [1–4].

<sup>62</sup> 

It is made available under a CC-BY 4.0 International license .

This review is limited to routine clinical care data (hereafter: routine data) derived from the health care system, such as EHR and administrative data including insurance and claims data. We focus on methodological challenges and biases that researchers may face when analyzing routine data.

75 For structuring an investigation on limitations, we suggest three scenarios, derived 76 from the field of clinical epidemiology where routine data hold high potential for 77 generating RWE: (1) Burden of Disease, (2) Safety and Risk Group Analysis, and (3) 78 Treatment Comparison. Burden of Disease describes the impact of a disease or 79 health problem on a specified population, quantified by metrics such as incidence, 80 prevalence, mortality, morbidity, quality of life, and economic impact [5]. As this 81 scenario typically includes the given health care setting in the definition of the study 82 population, we consider it as the most natural application of routine data. Safety and 83 Risk Group Analysis covers adverse events of various medical interventions such as 84 treatments, medications, devices and procedures, with a potential focus on 85 identifying and characterizing subgroups with a higher risk profile in the respective 86 population (e.g., due to comorbidities, genetic predispositions, or general 87 demographic characteristics) [6]. Here, routine data offer the possibility of long-term 88 observations, to study rare subgroups and adverse events, as well as to observe 89 patients with different comorbidities, and co-medications. As this scenario is 90 characterized by time-sensitive and potentially unobservable or undocumented 91 information, it is more complex than the Burden of Disease scenario. Treatment 92 Comparison deals with the causal effects of medical treatments. This area is and will 93 continue to be dominated by evidence from randomized controlled trials (RCTs). 94 However, with the beginning of 2025, a new EU regulation (2021/2282) for health 95 technology assessment (HTA) - a systematic assessment of the added benefits, 96 effectiveness, costs and impact of interventions, medication, devices or procedures

It is made available under a CC-BY 4.0 International license .

97 for further decision making- will enter into force [7]. Although the process is still in 98 development, health technology developers will need to address a high number of 99 PICO (Population, Intervention, Comparison, Outcome) schemes with diverse 100 comparators given that each state has its standards of care to generate sufficient 101 evidence for their technology [8]. Combined with the tight timelines in the joint clinical 102 assessment (EU-level HTA) process, clinical studies will not be available for all PICO 103 schemes, creating a high need for additional data sources like routine data. In 104 addition, routine data offer the opportunity to study the effects in a routine setting. 105 including effects of noncompliance, rare subgroups or subgroups not typically eligible 106 for clinical studies, confounding by indication as well as potential effects of site-107 specific impact factors on treatment outcome. Here, similar issues as in Safety and 108 *Risk Group Analysis* complicate the statistical analysis, especially due to the causal 109 interpretation of the primary outcome.

Although routine data are not primarily collected for research purposes, their use and longitudinal linkage with data from other sources such as registries or biobanks has the potential to improve health care and regulatory decision making [2,9]. However, it is not only the linkage to other data sources that is important but also the ability to aggregate data from different hospitals or even across different countries and health care systems given a common data model.

116 RCTs are the gold standard for answering questions about treatment efficacy and 117 safety. However, analyzing RWD may be useful to bridge evidence gaps at the 118 interface to clinical practice. Utilizing routine data offers several advantages, 119 including a large number of observations, especially when leveraging and linking 120 multiple clinical data sources. It allows the coverage of different locations, patient 121 populations (e.g., different age distribution or disease severity), and practice patterns 122 in routine health care [1,3,10]. Routine data analysis can also be valuable when

It is made available under a CC-BY 4.0 International license .

RCTs are not feasible due to ethical or practical reasons. Particularly in the context of treatment comparisons, the use of the target trial emulation framework allows to obtain comparable results to those observed in RCTs when carefully and fully emulated [7–9]. An alternative approach, rather than relying solely on routine data or their linkage for treatment comparison, is to use the data as an external control [2,10].


129 Yet, as routine data are documented for reimbursement or clinical care purposes, the 130 quality of the data from a research perspective is typically lower than that of other 131 prospectively planned studies - including RCTs. Routine data may lack 132 harmonization and interoperability, may often be incomplete and some relevant 133 information may be missing [4]. For instance, body mass index is generally irrelevant 134 for reimbursement purposes but might be a potential risk factor, confounder or effect 135 modifier for several research questions, especially in the field of non-communicable 136 diseases, such as those investigated by Zöller et al. [11] on chronic obstructive 137 pulmonary disease (COPD). The analysis of such data is therefore fraught with 138 methodological challenges, including confounding and several potential biases which 139 are already well-known from clinical epidemiology. Beyond these common concerns, 140 it remains unclear which additional limitations related to routinely collected data, 141 particularly challenges at measurement level – such as how data is collected and 142 translated into variables used for analysis – appear frequently [12].

143 In this work, we aim to provide an overview of the reported challenges and biases 144 inherent in routine data analysis with respect to their potential impact in the three 145 main scenarios. Consequently, we identify challenges that have a comparably high 146 potential to affect the analysis findings and require thorough consideration and 147 discussion in order to draw meaningful conclusions.

It is made available under a CC-BY 4.0 International license .

### 148 Methods

- To provide an overview of possible limitations in routine data analyses, we followed a step-wise approach visualized in Figure 1**Error! Reference source not found.** First, a systematic literature search of publications generating RWE within the predefined scenarios was conducted to obtain the limitations outlined in the respective discussion sections. Second, a subsequent focus group discussion with experts was held to supplement and to evaluate the identified list of challenges.
- 155 Figure 1 Process Flow Diagram



156

Overview of the process used in this work to identify and evaluate challenges and biases in routine care data analysis. This includes (1) a systematic literature search to extract and categorize reported limitations followed by (2) expert focus group discussions to supplement and discuss these challenges regarding their impact on real-world evidence.

- 161 Data sources and search strategies
- In October 2023, we conducted a systematic search of MEDLINE via PubMed. The search focused on English-language publications in the following top-ranked journals based on the Journal Citation Reports (JCR) category "Medicine, General & Internal" as of 2022 [13]: (i) The Lancet, (ii) New England Journal of Medicine, (iii) Journal of

It is made available under a CC-BY 4.0 International license .

166 the American Medical Association (JAMA) and (iv) British Medical Journal (BMJ). In 167 addition, we included the following oncology journals, based on our experience, as 168 RWE is particularly prevalent in this therapeutic field [14]: (v) JAMA Oncology, (vi) 169 The Lancet Oncology, and (vii) Journal of Clinical Oncology. In order to ensure 170 recency and thereby relevance of the articles, the search included all original articles 171 published between January 2018 and October 2023. The following terms were 172 queried in the title or abstract: "real-world evidence", "RWE", "Real-world data", "real-173 world", "routine data", "routine care data", "Emulation" and "Electronic health data". A 174 study was defined as being eligible if routine clinical care data collected by the 175 healthcare system, such as longitudinal claims data or EHR, was analyzed. Other 176 types of publications, such as comments, letters, perspectives or reviews were 177 excluded. Studies were also excluded, in which only registry data or manually 178 collected data were analyzed. In addition, we assessed if any aspect from the three 179 pre-defined scenario categories were investigated in the studies: (1) Burden of 180 Disease, (2) Safety and Risk Group Analysis, and (3) Treatment Comparison. If this 181 was not the case, the study was excluded. The detailed search strategy is described 182 in the Supplementary Material (Supplementary S1). All articles were indexed and 183 organized using Zotero.

184 Three reviewers (MP, KG, KU) independently screened each publication through all 185 stages of the review process. One reviewer (MP) independently screened all articles, 186 while the other two reviewers (KG, KU) distributed the articles between themselves 187 and reviewed them independently. First, titles and abstracts of the search results 188 were screened to ensure relevance and adherence to the inclusion and exclusion 189 criteria. In a second step, the full texts of the included abstracts were assessed to 190 obtain a final decision on inclusion in the review. In case of any discrepancy between 191 two reviewers regarding the eligibility of specific studies, an additional independent

It is made available under a CC-BY 4.0 International license .

reviewer (MB) was consulted to resolve the issue. The review was pre-specified andregistered in PROSPERO (CRD42023477616).

194

#### 195 Data extraction and categorization

196 Methodological challenges and limitations mentioned in the discussion sections of 197 the included publications were extracted as the main outcome. In addition, study 198 characteristics such as design, the underlying data sources, the country from which 199 data was obtained, the methods employed, and the purpose of the published studies 200 were retrieved. The extracted information was summarized in an Excel spreadsheet 201 (MP) and checked for accuracy (KG, KU). Publications were categorized into the 202 three predefined main areas of application (Burden of Disease, Safety and Risk 203 Group Analysis, Treatment Comparison), based on their research question. The 204 extracted limitations were subsequently assigned to the main bias categories in non-205 randomized studies as defined in the Cochrane Handbook: confounding, selection 206 bias, information bias and reporting bias [15]. Additionally, we derived categories by 207 grouping resembling limitations that seemed specific to the use of routine data (see 208 Results section).

We did not assess the quality or risk of bias of individual studies since we were not extracting data or outcomes of the studies for subsequent analysis and we were only interested in their stated limitations. Still, we expected that there were challenges not reported in the study publications, e.g., because of limited relevance or lack of awareness. Therefore, a subsequent focus group meeting was initiated for complementing and ranking the identified list of challenges.

#### 215 Focus Group

At a four-hour workshop, the results of the systematic literature search were presented in the form of a slide presentation for each scenario to a selected group.

218 The focus group members consisted of all associates of the EVA4MII project [16] 219 funded by the German Federal Ministry of Education and Research, which is 220 dedicated to building the infrastructure for methodological support in EHR data 221 analyses in Germany and to identifying the requirements of various interest holders. 222 In addition, one independent statistical expert from the area of health technology 223 assessments joined the discussion in order to specifically emphasize the 224 requirements for benefit assessment. All participants work in the field of (clinical) 225 epidemiology, medical biometry and statistics with background in mathematics or 226 informatics. After each scenario was presented, focus group members were asked to 227 add potential additional challenges in a moderated joint discussion. In addition, 228 through a General category, we left room for limitations and challenges that can be 229 found in RWD studies not specific to any of the three scenarios. All identified 230 challenges were listed for a subsequent voting on their potential impact within each 231 scenario. Every focus group member had two votes for each of the three main 232 scenarios, plus one additional vote for the General category. All challenges with at 233 least one vote were summarized and considered as key challenges deemed to have 234 a high potential to influence the evidence to be generated and require thorough 235 consideration in analyses. This assessment was based on the participants' 236 experience across numerous projects where they contributed to evaluation 237 components.

### 238 **Results**


#### 239 Study selection and characteristics

In total, 227 records were identified from MEDLINE of which 15 duplicate publications and 1 audio interview were removed, leading to 211 records eligible for title and abstract screening. From this first screening, we excluded 142 publications because

It is made available under a CC-BY 4.0 International license .

they were not original research articles, were only methods articles, or did not use routinely collected data from clinical care. In a second step, 69 records were evaluated in a full-text screening for verifying the data source as coming from electronic health records or administrative data, and to be categorizable into the three main scenarios. Finally, 39 studies were included in the review. An overview of the review process and study selection is depicted in Figure 2.

249 Figure 2 PRISMA flow diagram [17]



250

A brief summary of the study characteristics is shown in Table 1. Most of the studies were published in BMJ (36%), with 55% being published in the past two years (2022 and 2023). This is supporting our decision to limit the search to the past five years. The majority of extracted publications (46%) was based on data from the US. While

It is made available under a CC-BY 4.0 International license .

some publications used only EHR data (59%), other studies linked this information to additional sources, such as biobanks or registries (28%). The use of data sources varied between studies, from single-country to multinational studies. The highest proportion of the publications used nation-wide (46%) or multi-center data (38%), while the remaining studies used multi-national (10%), single-center (3%) and territory-wide (3%) data.

261 Table 1 Summary of study characteristics

Study Characteristics	n (%)
Journals	
BMJ	14 (35.9)
JAMA	
New England Journal of	4 (10.2)
Medicine	
	5 (12.8)
The Lancet	
JAMA Oncology	2 (5.1)
Journal of Clinical Oncology	5 (12.8)
The Lancet Oncology	0 (0)
Year	
2018	1 (2.6)
2019	5 (12.8)
2020	4 (10.3)
2021	7 (18.0)
2022	10 (25.6)
2023	12 (30.8)
Country	
Canada	1 (2.6)
France	1 (2.6)
Hong Kong	1 (2.6)
Israel	3 (7.7)
South Korea	1 (2.6)
UK	5 (12.8)
UK + Canada	1 (2.6)
UK + USA	2 (5.1)
USA	18 (46.2)
USA + South Korea	1 (2.6)
Qatar	1 (2.6)
>2 countries	4 (10.2)
Data Source	
EHR	23 (59.0)
EHR + additional linked	11 (28.2)
data*	
Administrative data**	5 (12.8)
Scope of Data	
single-center	1 (2.6)
multi-center	15 (38.5)

It is made available under a CC-BY 4.0 International license .

territory-wide	1 (2.6)
nation-wide	18 (46.2)
multi-national	4 (10.3)

262 In this table, the number of studies *n*, along with its percentage in brackets (%), is presented for

263 each category. EHR= Electronic health records

<sup>264</sup> \* additional linked data include exome sequencing data, hospital admission data, mortality data,

265 data from biobanks, claims data, questionnaire data, and data from registries

266 \*\* administrative data include insurance information and claims data

267 We identified five specific categories to highlight potential biases that are specific to 268 the use of routine data. First, as clinical routine data is primarily collected for 269 reimbursement purposes based on clinic-specific coding practices, the category 270 Coding Challenges is introduced. This category includes for example discrepancies 271 in coding practices between clinics or specificalities of the ICD10 (the International 272 Classification of Diseases and Related Health Problems) coding system [18]. This 273 challenge may lead to information bias, specifically misclassification or detection 274 bias, regardless of the already well-known detection bias, which typically result from 275 varying quality in detection methods. Second, as one of the main drivers of 276 documentation quality is again reimbursement as well as patient care rather than 277 research, the category Operationalization or Availability of Variables is established to 278 address to which extent studies were restricted by the availability of the data for 279 answering the research question. This type of missing data may lead to unmeasured 280 confounding and potential selection bias. Third, routine data may suffer from other 281 types of missing data, i.e., missing records in certain variables, as typically known 282 from observational studies, resulting in the category Missing Data. Fourth, routine 283 data may also suffer from different lengths of follow-up largely varying between 284 patients, for which we introduce a further category called *Follow-up Challenges*. 285 Finally, the category Validation & Data Quality is added, which leads to potential bias

as large amounts of routine data typically cannot be carefully validated. This also
includes the variability of data quality over time arising e.g., due to changes in coding
systems, such as transitions between versions of the ICD coding standard, or the
ongoing digitalization of hospitals. An overview of the types of biases and limitations
are presented in the Supplementary Material S2 – Table S3.

291 Table 2 provides a summary of the limitations mentioned in the discussion section of 292 the extracted studies stratified into the data source types and according to their 293 assigned scenario category. In total, there are 11 publications in the category Burden 294 of Disease, 17 publications in Safety and Risk Group Analysis and 11 publications in 295 Treatment Comparison. As expected, the main bias types are typically mentioned in 296 the publications. However, it is important to recognize the additional biases that 297 frequently appear. A detailed overview for each publication is provided in the 298 Supplementary Material S3 – Table S4, including a broad overview of the study 299 design including the main outcomes and their respective methods, objectives, and 300 the scope of the analysis in terms of data use.

#### 301 Table 2 Summary of biases extracted from the studies

			Main Bias Cate	egories		Additional Bias Categories						
		Total	Confounding	Selection Bias	Information Bias	Reporting Bias	Coding Challenges	Operationali zation or Availability of Variables	Missing Data	Follow-up Challenges	Validation & Data Quality	
of e	EHR	21	3 (14%)	4 (19%)	5 (24%)	2 (10%)	2 (10%)	2 (10%)	3 (14%)	1		
Burden of Disease	Linked EHR	13	2 (15%)	3 (23%)	2 (15%)	1 (8%)			1 (8%)	2 (15%)	2 (15%)	
B	Admin. Data	1		1 (100%)								
Risk P	EHR	28	7 (25%)	4 (14%)	5 (18%)	2 (7%)		3 (11%)	2 (7%)	3 (11%)	2 (7%)	
Safety & R Group	Linked EHR	25	4 (16%)	4 (16%)	6 (24%)	4 (16%)	2 (8%)	1 (4%)	2 (8%)		2 (8%)	
Safe	Admin. Data	12	2 (17%)	2 (17%)	2 (17%)	1 (8%)		2 (17%)	1 (8%)	2 (17%)		
paris	EHR	32	9 (28%)	9 (28%)	7 (22%)		1 (3%)	3 (9%)	2 (6%)		1 (3%)	

It is made available under a CC-BY 4.0 International license .


Linke EHR	d 0				
Admiı Data	<sup>n.</sup> 6	2 (33%)	2 (33%)	1 (17%)	1 (17%)
302		·			
303		Number (	percentage)	of studies	facing the main biases and additional identified bias
304	categ	ories groupe	ed by data so	ource types	and the main scenarios: Burden of Disease, Safety and
305	Risk	Group Ana	lysis, and	Treatment	Comparison. Abbreviations: EHRElectronic Health
306	Reco	ords, Admin. [	Data Admi	nistrative D	lata
307					

308 In Figure 3, all challenges that were added and ranked according to their relevance in

309 the focus group discussion are summarized.

It is made available under a CC-BY 4.0 International license .

#### 310 Figure 3 Overview of Workshop Results



It is made available under a CC-BY 4.0 International license .

312 Findings of the focus group discussion divided into the three main scenarios: Burden of 313 Disease, Safety and Risk Group Analysis, and Treatment Comparison, as well as the additional 314 category General Limitations. The content stated within the blue colored areas are the voting 315 results. All bullet points in this area were deemed important, with the plus signs representing the 316 number of votes received. A single plus sign (+) indicates sporadic votes, whereas three plus 317 signs (+++) denote a majority vote. The blue font highlights challenges and limitations identified in 318 the systematic search, whereas the black font denotes those added by the focus group. The 319 challenges and limitations listed outside the blue area did not receive any votes of particular 320 importance from the focus group.

321

In the following, we outline the findings on methodological challenges and limitations from both the review and the focus group workshop for each main scenario, separately.

325

#### 326 Burden of disease

327 Five publications reported limitations potentially leading to confounding. Of these, two 328 studies had limited availability of variables included in the analysis resulting in the 329 possibility of unmeasured confounding [19,20]. However, Kamran et al. [20] argued 330 that with the use of a limited number of variables in the model a reliable identification 331 and validation of all variables even across different institutions was feasible. 332 Limitations related to the risk of selection bias were present in eight studies. On the 333 one hand, in Canavan et al. [19] a volunteer bias could not be ruled out because the 334 data used for the analyses included individuals who opted to be included in the study 335 database. On the other hand, in Witberg et al. [21] the absence of simultaneously 336 enrolled comparison groups was mentioned which could lead to a potential selection 337 bias. Moreover, some studies highlighted the fact that the results might not be 338 transferable to other clinical practices or populations [19,22–24]. The primary type of

It is made available under a CC-BY 4.0 International license .

339 information bias (n=7) observed was misclassification bias, affecting either the 340 exposure or outcome [19,22,25,26]. Beck et al. [22] highlighted that clinical 341 diagnoses were probably not fully captured due to challenges in diagnostic and 342 physician coding. On the other hand, Manz et al. [26] noted a limitation indicating that 343 they were limited to use only patients with a coded classifier variable for comparing 344 the machine learning model with the commonly used prognostic reference. This 345 limitation resulted from differences in the characteristics of the patients with and 346 without the coded variable. Kamran et al. [20] additionally emphasized that even 347 though a common EHR provider across facilities was implemented, it remains crucial 348 to have in-depth knowledge of the local deployment. Two studies reported limited 349 follow-up time [24,27]. However, Biccler et al. [27] noted that despite the longer 350 follow-up period compared to clinical trials, it was still insufficient to evaluate very 351 long-term effects. The lack of health record validation was reported in two studies 352 [27,28]. While all studies acknowledged limitations in their discussions, only three 353 studies [20,23,25] took an additional step to assess these limitations in the context of 354 their specific study.

355 During the focus group discussion, further limitations were added to those identified 356 in the literature review and are presented in the first part of Figure 3. Some relevant 357 and reasonable limitations added by the experts were the inconsistency of the data 358 quality over time. This challenge is interconnected to the adjustment or calibration of 359 algorithms to dynamic data changes, especially when using a model that 360 continuously uses recent data from routine clinical care. Additionally, the 361 heterogeneity and specialization of hospitals substantially impact the burden of 362 disease. Including only hospitals with specializations in a certain disease treatment 363 would overestimate the burden. Another added limitation was missing information

It is made available under a CC-BY 4.0 International license .

364 *due to death* in situations with death as competing risk, where it would be impossible

to diagnose the disease even though the patient may have had it [29].

366 The rating of the limitations of Burden of Disease is indicated by the blue area in 367 Figure 3. The transferability of study results to a larger population, which goes hand 368 in hand with the possibilities of selection bias, missing data and misclassification of 369 data, was weighted by the experts to be most important. The importance of data 370 quality in EHR data was also recognized, specifically the variability of data quality 371 over time due to e.g., changes in coding systems, such as transitions between 372 versions of the ICD coding standard, or individual coding behavior. This could 373 potentially introduce bias to the results concerning the burden of a disease, 374 particularly when comparing diagnoses from the present to the past or the burden 375 over an extended period of time.

#### 376 Safety and Risk Group Analysis

377 In this category, the information bias was predominantly manifested as the risk for 378 misclassification bias [30–38] with only one study addressing immortal time bias [36]. 379 Specifically, certain limitations were connected with coding challenges, since the 380 classification was based on diagnosis codes from the EHR systems [31,33]. In 381 addition, some form of potential information bias occurred because the drug use in 382 an EHR system had been defined as the prescription of the medication and not as 383 the actual drug intake [34,39]. Aspects like the quantification and analysis of 384 information concerning the physician's decision-making process for treatment 385 selection, treatment switching or the effect of pre-treatment were often missing or 386 inadequately explored [36,38,40] which could lead to confounded results. Details 387 regarding adherence or dosage, as well as unstructured free-text information, were 388 not accessible [38,40,41]. Additionally, significant risk factors, such as smoking, were 389 not available, creating a potentially high risk of confounding in the analysis. Selection

It is made available under a CC-BY 4.0 International license .

390 bias limitations were evident in ten studies including volunteer bias due to the 391 involvement of individuals who volunteered to join the database used for analysis 392 [33,42]. Moreover, several studies highlighted site heterogeneity, noting that certain 393 hospitals with robust programs may have had a higher burden of disease [31-33]. 394 The limitation of missing data was mentioned in five studies [31,34,36,37,43], for 395 instance, in Li et al. [34] who stated that EHR data sources lacked comprehensive 396 coverage of medical events recorded in other healthcare facilities. While only three 397 studies [36,41,42] explicitly stated their limitations without providing further 398 elaboration, the remaining studies either addressed how they mitigated certain 399 limitations through selected methodologies or sensitivity analyses [32,34,35,37-40,44]. 400 Alternatively, they presented arguments explaining why certain limitations were 401 unlikely or invalid in the context of their specific study [30,31,33,37,43,45].

402 A few specific challenges were added by the experts in the focus group discussion as 403 displayed in the second section of Figure 3. First, it is considered important to 404 correctly distinguish between the case and patient definition. Given that patients may 405 have multiple cases associated with them in routine clinical data, it is essential for the 406 research question to specify whether the data refers to the patient level or the 407 individual case level. The lack of clarity could potentially violate the i.i.d-assumptions 408 (independent and identically distributed assumption), which is the basis for many 409 commonly used statistical methods.

Second, another challenge mentioned is the problem of reverse p-hacking for safety endpoints, where the analysis is manipulated to intentionally favor non-significant results [46]. Third, the focus group emphasized the importance of the limitation related to the lack of follow-up data, especially in health care systems where no linkage with routine outcome information is available. A longer follow-up period is crucial for conducting thorough safety analyses to observe adverse events. This

It is made available under a CC-BY 4.0 International license .

416 aspect is closely linked to the issue of missing information due to death, as death417 prevents the observation of subsequent adverse events.

Moreover, the experts added several limitations related to medication use. These included insufficient information on the reasons for change in medication and its effect, as well as information on dosage. Additionally, concerns were raised about the off-label use of medication. Unlike in controlled clinical trials, the treatment paths of patients are quite heterogeneous due to the decisions of the clinician or the different specializations of the hospitals.

#### 424 Treatment Comparison

425 Confounding remained a particular area of concern, specifically in achieving balance 426 between the groups. Kim et al. [47] reported persistent imbalance in variables even 427 after applying matching techniques. However, they addressed this issue by adjusting 428 for these variables in further analyses. Likewise, Xie et al. [48] stated that individuals 429 treated with the study medication had a higher baseline health burden, potentially 430 leading to underestimated findings due to residual confounding. Only two studies 431 explicitly report missing risk factors that could subsequently not be used for balancing 432 [49,50]. Wang et al. [51] highlighted that claims data had not recorded medication 433 use in hospital, therefore, they needed to use alternative index date and follow-up 434 definition. Similar to the Safety and Risk Group Analysis, most potential information 435 biases were a type of misclassification [48,52–55]. Rentsch et al. [50] reported that 436 the identification of outcome events was not provided by a validated algorithm, which 437 could also potentially lead to information bias. Same holds true for Wong et al. [56] 438 as they did not distinguish the reason for deaths. Kim et al. [47] emphasized the 439 general issues of immortal time and time lag biases in the discussion section, but 440 elaborated on the methods used to address and avoid these biases. One study noted 441 the concern of potential upcoding, i.e. the intentional use of ICD-10 and OPS

It is made available under a CC-BY 4.0 International license .

442 (Operation and Procedure Classification System) codes with the greatest 443 reimbursement rather than those with the greatest clinical relevance, resulting in 444 overstating the patient's severity of disease [57]. Xie et al. [54] highlighted that the 445 effectiveness of the investigated drug could be overestimated in individuals with poor 446 health characteristics who opt not to receive treatment, while those with better health 447 characteristics who decide not to be treated could lead to underestimation. The 448 studies predominantly stated their open limitations including those that persisted 449 despite implementing causal inference methods or conducting sensitivity analyses 450 aimed at addressing them [48,50,52,54]. Beyond that, Kim et al. [47] detailed how 451 they mitigated their limitations.

452 The focus group discussion resulted in the following additions. First, data availability 453 with regard to the transferability within different health care sectors, e.g., ambulatory 454 and stationary sector, was added as challenge, especially for Germany [58]. Second, 455 the timing of an intervention is also critical to assess its effectiveness accurately, 456 understand its impact on patient outcomes, and make informed clinical decisions. In 457 EHR or administrative databases, the timing may not be explicitly recorded or may be 458 subject to errors or omissions. Third, the difficulty in defining control groups for 459 comparison was highlighted as well as the verifiability of the inclusion or exclusion 460 criteria [59,60]. Fourth, similar to the Safety and Risk Group Analysis scenario, 461 follow-up duration is critical. However, in the context of treatment comparison, the 462 criticality arises also from the possibility that drugs can have a longer delay in 463 efficacy.

464 Compared to the previous scenarios the ratings of the *Treatment Comparison*465 category were more widely distributed, with votes spread across numerous
466 limitations. This distribution highlighted the wide range of challenges to consider.
467 Residual confounding and immortal time bias received the majority of votes. Not only

It is made available under a CC-BY 4.0 International license .

the data availability of different data sectors, but also the availability of variables was
considered important which is connected to residual confounding, e.g. absence of
known confounders.

#### 471 General limitations and challenges

The focus group viewed the linkage of records, the validation of data and the selection of measurements as critical to conduct routine care data analysis. If there are multiple measurements, it can be challenging to specify which measurement is considered as the relevant one. In connection with record-linkage, both with other hospitals and other data sources, the cases and patient data may overlap between hospitals and other data sources. In addition, the challenges with the definition of estimands and estimators was highlighted [6,61,62].

### 479 **Discussion**

This review aimed to present a comprehensive overview of the limitations and biases inherent in the analysis of routine clinical care data. Additionally, we pinpointed the challenges with the greatest potential to influence the results of the analysis emphasizing thorough consideration and discussion for the derivation of meaningful inference. We have intentionally provided a comprehensive overview of the study's features to serve as a guide, categorically organized into different scenarios.

While our focus was specifically on limitations stated in the discussion section of publications, we did not provide explicit methods to address these limitations but emphasized which studies mitigated biases or explained why certain limitations were deemed unlikely. However, methods to handle limitations have already been partially discussed in other works [63,64]. In the extracted publications, various approaches were applied to address confounding, such as large scale propensity score model, matching, inverse probability of treatment weights, active comparator, prevalent new

It is made available under a CC-BY 4.0 International license .

493 user design, quantitative bias analysis with e-values and confounder adjustment 494 [25,30,32,35,38–40,50,52,53]. In order to diminish publication bias and p-hacking, 495 Suchard et al.[39] made all results available through an interactive website, 496 facilitating correction for multiple testing. To address missing data, studies applied 497 multiple imputation with subsequent sensitivity analysis, or performed complete case 498 analysis [31,34,37]. By conducting subgroup analyses based on the duration of 499 follow-up, Filion et al.[32] mitigate concerns about the limitation of short median 500 follow-up, while Cohen-Stavi et al.[30] focused solely on short-term effectiveness due 501 to limited follow-up time. Heterogeneity between sites was accounted for by using a 502 random effects model [32]. Some limitations were addressed by referencing previous 503 studies [34,50]. Finally, several studies have conducted a target trial emulation to 504 mimic controlled trials and thus infer causality for observational data 505 [30,35,43,48,51,52,54,57,65].

506 Naturally, this study is also subject to limitations. Firstly, by restricting our search 507 strategy to high-impact publications from 2018 onwards for the sake of recency and 508 relevance, there is a possibility that we overlooked certain publications and their 509 associated limitations. However, the incorporation of expert experiences and 510 knowledge may cover missed challenges. In addition, data sources from high-impact 511 publications may be of higher quality which can inherently reduce the limitations 512 encountered. Second, given that our panel consisted solely of self-selected German 513 experts in the field of statistics and clinical epidemiology, the added limitations might 514 be influenced by local challenges specific to this context and might miss the 515 important aspects such as the international or the clinical perspective. Finally, this 516 review only included studies that were successfully published implying a publication 517 bias. Therefore, we could not identify challenges that prevented successful data 518 analyses and publication.

519 Our study assessed various limitations faced across different study scenarios of 520 interest, resulting in a ranked list of potentially relevant challenges. In the next step, 521 we aim to explore the requirements and concerns of various interest holders 522 regarding the use of routine clinical data to achieve different objectives, particularly in 523 therapeutic evaluations. This will involve understanding the diverse expectations, 524 needs, and potential challenges faced by interest holders in leveraging routine 525 clinical data for meaningful and accurate therapeutic assessments.

### 526 Conclusion

527 This review provides a comprehensive examination of potential limitations and biases 528 in analyses of routine clinical care data reported in recent high-impact journals. 529 Based on expert's opinion, we highlighted challenges that could have a high potential 530 to influence analysis results, stressing the necessity for thorough consideration and 531 discussion to derive meaningful conclusions.

532

se
5
n

### 534 Ethics approval and consent to participate

535 Not applicable

It is made available under a CC-BY 4.0 International license .

# 536 Consent for publication

- 537 Not applicable
- 538 Availability of data and materials
- 539 Not applicable
- 540 Competing interests
- 541 The authors declare that they have no competing interests.

# 542 Funding

This work was funded by the Federal Ministry of Education and Research (BMBF) in Germany in the framework of the EVA4MII project (FKZ 01ZZ2308A, 01ZZ2308B, 01ZZ2308C). The funding agency had no role in the design, data collection, analyses, interpretation, and reporting of the study. The work of HB, MB, and NB has also been funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) – Project-ID 499552394 – SFB 1597.

# 549 Authors' contributions

550 MP, DZ, HB and NB developed the study conception and design. MP, MB, KU and 551 KG were involved in the systematic search process. MP extracted the data from the 552 publications. KU and KG critically reviewed the extraction. MP wrote the first draft of 553 the manuscript; NB supervised this process. MB, DZ, HB, VR, JRP, PH, MK, FR and 554 AS provided additional intellectual content to the manuscript. All authors critically 555 reviewed and approved the final version.

It is made available under a CC-BY 4.0 International license .

## 556 Acknowledgments

- 557 We would like to thank the participants of the focus group workshop for the joint
- 558 discussion.

- 560 **References**
- Sherman RE, Anderson SA, Dal Pan GJ, Gray GW, Gross T, Hunter NL, et al. Real-561 [1] World Evidence — What Is It and What Can It Tell Us? N Engl J Med 2016;375:2293–7. 562 https://doi.org/10.1056/NEJMsb1609216. 563 564 [2] Rahman R, Ventz S, McDunn J, Louv B, Reyes-Rivera I, Polley M-YC, et al. 565 Leveraging external data in the design and analysis of clinical trials in neuro-oncology. 566 Lancet Oncol 2021;22:e456–65. https://doi.org/10.1016/S1470-2045(21)00488-5. 567 Franklin JM, Schneeweiss S. When and How Can Real World Data Analyses [3] 568 Substitute for Randomized Controlled Trials? Clin Pharmacol Ther 2017;102:924–33. 569 https://doi.org/10.1002/cpt.857. [4] 570 Liu F, Panagiotakos D. Real-world data: a brief review of the methods, applications, 571 challenges and opportunities. BMC Med Res Methodol 2022;22:287. 572 https://doi.org/10.1186/s12874-022-01768-6. 573 Hessel F. Burden of DiseaseBurdenof disease(s). In: Kirch W, editor. Encycl. Public [5] 574 Health, Dordrecht: Springer Netherlands; 2008, p. 94–6. https://doi.org/10.1007/978-1-4020-575 5614-7 297. 576 [6] Unkel S, Amiri M, Benda N, Beyersmann J, Knoerzer D, Kupas K, et al. On 577 estimands and the analysis of adverse events in the presence of varying follow up times 578 within the benefit assessment of therapies. Pharm Stat 2019;18:166-83. 579 https://doi.org/10.1002/pst.1915. 580 European Commission: Directorate-General for Health and Food Safety. [7] 581 Implementing the EU health technology assessment regulation. Publications Office of the 582 European Union; 2023. https://doi.org/10.2875/246730. 583 [8] Buchholz I. PT28 Lost in PICO? a Simulation of the EU HTA Scoping Process n.d. 584 [9] Cowie MR, Blomster JI, Curtis LH, Duclaux S, Ford I, Fritz F, et al. Electronic health 585 records to facilitate clinical research. Clin Res Cardiol 2017;106:1-9. 586 https://doi.org/10.1007/s00392-016-1025-6. 587 Sheldrick RC. Randomized Trials vs Real-world Evidence: How Can Both Inform [10] 588 Decision-making? JAMA 2023;329:1352–3. https://doi.org/10.1001/jama.2023.4855. 589 Zöller D, Haverkamp C, Makoudjou A, Sofack G, Kiefer S, Gebele D, et al. Alpha-1-[11] 590 antitrypsin-deficiency is associated with lower cardiovascular risk: an approach based on 591 federated learning. Respir Res 2024;25:38. https://doi.org/10.1186/s12931-023-02607-y. 592 Schneeweiss S. Von Real-World-Daten zur Real-World-Evidenz: eine praktische [12] 593 Anleitung. Prävent Gesundheitsförderung 2023. https://doi.org/10.1007/s11553-023-01026-7. 594 [13] 2022 Journal Impact Factor, Journal Citation Reports (Clarivate, 2023) n.d. 595 Purpura CA, Garry EM, Honig N, Case A, Rassen JA. The Role of Real World [14] 596 Evidence in FDA Approved New Drug and Biologics License Applications. Clin Pharmacol 597 Ther 2022;111:135–44. https://doi.org/10.1002/cpt.2474. 598 Sterne JAC, Hernán MA, McAleenan A, Reeves BC, Higgins JPT. Chapter 25: [15] 599 Assessing risk of bias in a non-randomized study. In: Higgins JPT, Thomas J, Chandler J, 600 Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic 601 Reviews of Interventions version 6.4 (updated August 2023). Cochrane, 2023. Available from

- 602 : www.training.cochrane.org/handbook.
- 603 [16] EVA4MII- EVAluation research based on data from routine clinical care 4 the MII
- 604 2024. https://ukw.de/eva4mii (accessed November 8, 2024).
- 605 [17] Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al.
- 606 The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst
- 607 Rev 2021;10:89. https://doi.org/10.1186/s13643-021-01626-4.
- 608 [18] World Health Organization. ICD-10: international statistical classification of
- 609 diseases and related health problems : tenth revision, 2nd ed. World Health Organization.
- 610 2004. https://iris.who.int/handle/10665/42980.
- 611 [19] Canavan M, Wang X, Ascha M, Miksad R, Showalter TN, Calip G, et al. End-of-Life
- 612 Systemic Oncologic Treatment in the Immunotherapy Era: The Role of Race, Insurance, and
- 613 Practice Setting. J Clin Oncol Off J Am Soc Clin Oncol 2023;41:4729–38.
- 614 https://doi.org/10.1200/JCO.22.02180.
- 615 [20] Kamran F, Tang S, Otles E, McEvoy DS, Saleh SN, Gong J, et al. Early identification
- of patients admitted to hospital for covid-19 at risk of clinical deterioration: model
- 617 development and multisite external validation study. BMJ 2022;376:e068576.
- 618 https://doi.org/10.1136/bmj-2021-068576.
- 619 [21] Witberg G, Barda N, Hoss S, Richter I, Wiessman M, Aviv Y, et al. Myocarditis after
- 620 Covid-19 Vaccination in a Large Health Care Organization. N Engl J Med 2021;385:2132–9.
  621 https://doi.org/10.1056/NEJMoa2110737.
- 622 [22] Beck DB, Bodian DL, Shah V, Mirshahi UL, Kim J, Ding Y, et al. Estimated
- 623 Prevalence and Clinical Manifestations of UBA1 Variants Associated With VEXAS
- 624 Syndrome in a Clinical Population. JAMA 2023;329:318–24.
- 625 https://doi.org/10.1001/jama.2022.24836.
- 626 [23] Forrest IS, Petrazzini BO, Duffy Á, Park JK, Marquez-Luna C, Jordan DM, et al.
- 627 Machine learning-based marker for coronary artery disease: derivation and validation in two
- longitudinal cohorts. Lancet Lond Engl 2023;401:215–25. https://doi.org/10.1016/S0140 6736(22)02079-7.
- [24] Vasileiou E, Simpson CR, Shi T, Kerr S, Agrawal U, Akbari A, et al. Interim findings
   from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in
- 632 Scotland: a national prospective cohort study. Lancet Lond Engl 2021;397:1646–57.
- 633 https://doi.org/10.1016/\$0140-6736(21)00677-2.
- 634 [25] Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, et al. Impact and
- 635 effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19
- cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an
   observational study using national surveillance data. Lancet Lond Engl 2021;397:1819–29.
- 638 https://doi.org/10.1016/S0140-6736(21)00947-8.
- 639 [26] Manz CR, Chen J, Liu M, Chivers C, Regli SH, Braun J, et al. Validation of a
- 640 Machine Learning Algorithm to Predict 180-Day Mortality for Outpatients With Cancer.
- 641 JAMA Oncol 2020;6:1723–30. https://doi.org/10.1001/jamaoncol.2020.4331.
- 642 [27] Biccler JL, Glimelius I, Eloranta S, Smeland KB, Brown P de N, Jakobsen LH, et al.
- 643 Relapse Risk and Loss of Lifetime After Modern Combined Modality Treatment of Young
- Patients With Hodgkin Lymphoma: A Nordic Lymphoma Epidemiology Group Study. J Clin
  Oncol Off J Am Soc Clin Oncol 2019;37:703–13. https://doi.org/10.1200/JCO.18.01652.
- 646 [28] Chang AR, Moore BS, Luo JZ, Sartori G, Fang B, Jacobs S, et al. Exome Sequencing
- 647 of a Clinical Population for Autosomal Dominant Polycystic Kidney Disease. JAMA
- 648 2022;328:2412–21. https://doi.org/10.1001/jama.2022.22847.
- 649 [29] Binder N, Blümle A, Balmford J, Motschall E, Oeller P, Schumacher M. Cohort
- 650 studies were found to be frequently biased by missing disease information due to death. J Clin
- 651 Epidemiol 2019;105:68–79. https://doi.org/10.1016/j.jclinepi.2018.09.010.
- 652 [30] Cohen-Stavi CJ, Magen O, Barda N, Yaron S, Peretz A, Netzer D, et al. BNT162b2

653 Vaccine Effectiveness against Omicron in Children 5 to 11 Years of Age. N Engl J Med 654 2022;387:227-36. https://doi.org/10.1056/NEJMoa2205011. 655 Damrauer SM, Chaudhary K, Cho JH, Liang LW, Argulian E, Chan L, et al. [31] 656 Association of the V122I Hereditary Transthyretin Amyloidosis Genetic Variant With Heart 657 Failure Among Individuals of African or Hispanic/Latino Ancestry. JAMA 2019;322:2191-658 202. https://doi.org/10.1001/jama.2019.17935. 659 Filion KB, Lix LM, Yu OH, Dell'Aniello S, Douros A, Shah BR, et al. Sodium [32] 660 glucose cotransporter 2 inhibitors and risk of major adverse cardiovascular events: multi-661 database retrospective cohort study. BMJ 2020;370:m3342. 662 https://doi.org/10.1136/bmj.m3342. 663 Forrest IS, Chaudhary K, Vy HMT, Petrazzini BO, Bafna S, Jordan DM, et al. [33] 664 Population-Based Penetrance of Deleterious Clinical Variants. JAMA 2022;327:350–9. 665 https://doi.org/10.1001/jama.2021.23686. 666 Li X, Ostropolets A, Makadia R, Shoaibi A, Rao G, Sena AG, et al. Characterising the [34] 667 background incidence rates of adverse events of special interest for covid-19 vaccines in eight 668 countries: multinational network cohort study. BMJ 2021;373:n1435. 669 https://doi.org/10.1136/bmj.n1435. 670 Lyu H, Zhao SS, Zhang L, Wei J, Li X, Li H, et al. Denosumab and incidence of type [35] 671 2 diabetes among adults with osteoporosis: population based cohort study. BMJ 672 2023;381:e073435. https://doi.org/10.1136/bmj-2022-073435. Martin P, Cohen JB, Wang M, Kumar A, Hill B, Villa D, et al. Treatment Outcomes 673 [36] 674 and Roles of Transplantation and Maintenance Rituximab in Patients With Previously 675 Untreated Mantle Cell Lymphoma: Results From Large Real-World Cohorts. J Clin Oncol 676 Off J Am Soc Clin Oncol 2023;41:541–54. https://doi.org/10.1200/JCO.21.02698. 677 Seymour CW, Kennedy JN, Wang S, Chang C-CH, Elliott CF, Xu Z, et al. Derivation, [37] 678 Validation, and Potential Treatment Implications of Novel Clinical Phenotypes for Sepsis. 679 JAMA 2019;321:2003–17. https://doi.org/10.1001/jama.2019.5791. 680 [38] You SC, Rho Y, Bikdeli B, Kim J, Siapos A, Weaver J, et al. Association of 681 Ticagrelor vs Clopidogrel With Net Adverse Clinical Events in Patients With Acute Coronary 682 Syndrome Undergoing Percutaneous Coronary Intervention. JAMA 2020;324:1640–50. 683 https://doi.org/10.1001/jama.2020.16167. 684 [39] Suchard MA, Schuemie MJ, Krumholz HM, You SC, Chen R, Pratt N, et al. 685 Comprehensive comparative effectiveness and safety of first-line antihypertensive drug 686 classes: a systematic, multinational, large-scale analysis. Lancet Lond Engl 2019;394:1816– 687 26. https://doi.org/10.1016/S0140-6736(19)32317-7. 688 Vinogradova Y, Coupland C, Hill T, Hippisley-Cox J. Risks and benefits of direct oral [40] 689 anticoagulants versus warfarin in a real world setting: cohort study in primary care. BMJ 690 2018;362:k2505. https://doi.org/10.1136/bmj.k2505. 691 Chavez-MacGregor M, Lei X, Zhao H, Scheet P, Giordano SH. Evaluation of [41] 692 COVID-19 Mortality and Adverse Outcomes in US Patients With or Without Cancer. JAMA 693 Oncol 2022;8:69-78. https://doi.org/10.1001/jamaoncol.2021.5148. 694 Berry ASF, Finucane BM, Myers SM, Abril A, Kirchner HL, Ledbetter DH, et al. [42] 695 Association of Supernumerary Sex Chromosome Aneuploidies With Venous 696 Thromboembolism. JAMA 2023;329:235–43. https://doi.org/10.1001/jama.2022.23897. 697 [43] Deng Y, Polley EC, Wallach JD, Dhruva SS, Herrin J, Quinto K, et al. Emulating the 698 GRADE trial using real world data: retrospective comparative effectiveness study. BMJ 699 2022;379:e070717. https://doi.org/10.1136/bmj-2022-070717. 700 Chemaitelly H, AlMukdad S, Ayoub HH, Altarawneh HN, Coyle P, Tang P, et al. [44] 701 Covid-19 Vaccine Protection among Children and Adolescents in Qatar. N Engl J Med 702 2022;387:1865-76. https://doi.org/10.1056/NEJMoa2210058. 703 Harstad E, Shults J, Barbaresi W, Bax A, Cacia J, Deavenport-Saman A, et al. α2-[45]

It is made available under a CC-BY 4.0 International license .

704 Adrenergic Agonists or Stimulants for Preschool-Age Children With Attention-

- 705 Deficit/Hyperactivity Disorder. JAMA 2021;325:2067–75.
- 706 https://doi.org/10.1001/jama.2021.6118.
- 707 Chuard PJC, Vrtílek M, Head ML, Jennions MD. Evidence that nonsignificant results [46]
- 708 are sometimes preferred: Reverse P-hacking or selective reporting? PLOS Biol
- 709 2019;17:e3000127. https://doi.org/10.1371/journal.pbio.3000127.
- 710 Kim NH, Han KH, Choi J, Lee J, Kim SG. Use of fenofibrate on cardiovascular [47]
- 711 outcomes in statin users with metabolic syndrome: propensity matched cohort study. BMJ 712 2019;366:15125. https://doi.org/10.1136/bmj.15125.
- 713
- [48] Xie Y, Bowe B, Al-Aly Z. Molnupiravir and risk of hospital admission or death in
- 714 adults with covid-19: emulation of a randomized target trial using electronic health records.
- 715 BMJ 2023;380:e072705. https://doi.org/10.1136/bmj-2022-072705.
- 716 [49] Mahévas M, Tran V-T, Roumier M, Chabrol A, Paule R, Guillaud C, et al. Clinical
- 717 efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen:
- 718 observational comparative study using routine care data. BMJ 2020;369:m1844.
- 719 https://doi.org/10.1136/bmj.m1844.
- 720 [50] Rentsch CT, Beckman JA, Tomlinson L, Gellad WF, Alcorn C, Kidwai-Khan F, et al.
- 721 Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019
- 722 mortality in patients admitted to hospital in the United States: cohort study. BMJ
- 723 2021;372:n311. https://doi.org/10.1136/bmj.n311.
- 724 [51] Wang SV, Schneeweiss S, Franklin JM, Desai RJ, Feldman W, Garry EM, et al. 725 Emulation of Randomized Clinical Trials With Nonrandomized Database Analyses: Results
- 726 of 32 Clinical Trials. JAMA 2023;329:1376–85. https://doi.org/10.1001/jama.2023.4221.
- 727 [52] Andersson NW, Thiesson EM, Baum U, Pihlström N, Starrfelt J, Faksová K, et al. 728 Comparative effectiveness of bivalent BA.4-5 and BA.1 mRNA booster vaccines among 729 adults aged  $\geq$ 50 years in Nordic countries: nationwide cohort study. BMJ 2023;382:e075286. 730 https://doi.org/10.1136/bmj-2022-075286.
- 731 Deputy NP, Deckert J, Chard AN, Sandberg N, Moulia DL, Barkley E, et al. Vaccine [53] 732 Effectiveness of JYNNEOS against Mpox Disease in the United States. N Engl J Med 733 2023;388:2434-43. https://doi.org/10.1056/NEJMoa2215201.
- 734 Xie Y, Bowe B, Al-Aly Z. Nirmatrelvir and risk of hospital admission or death in [54] 735 adults with covid-19: emulation of a randomized target trial using electronic health records. 736 BMJ 2023;381:e073312. https://doi.org/10.1136/bmj-2022-073312.
- 737 [55] Zheng B, Green ACA, Tazare J, Curtis HJ, Fisher L, Nab L, et al. Comparative 738 effectiveness of sotrovimab and molnupiravir for prevention of severe covid-19 outcomes in 739 patients in the community: observational cohort study with the OpenSAFELY platform. BMJ 740 2022;379:e071932. https://doi.org/10.1136/bmj-2022-071932.
- 741 [56] Wong CKH, Au ICH, Lau KTK, Lau EHY, Cowling BJ, Leung GM. Real-world 742 effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, 743 and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed
- 744 SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study.
- 745 Lancet Lond Engl 2022;400:1213–22. https://doi.org/10.1016/S0140-6736(22)01586-0.
- 746 [57] Marafino BJ, Escobar GJ, Baiocchi MT, Liu VX, Plimier CC, Schuler A. Evaluation 747 of an intervention targeted with predictive analytics to prevent readmissions in an integrated
- 748 health system: observational study. BMJ 2021;374:n1747. https://doi.org/10.1136/bmj.n1747.
- 749 [58] Lang C, Gottschall M, Sauer M, Köberlein-Neu J, Bergmann A, Voigt K. "Da kann
- 750 man sich ja totklingeln, geht ja keiner ran" – Schnittstellenprobleme zwischen stationärer,
- 751 hausärztlicher und ambulant-fachspezialisierter Patientenversorgung aus Sicht Dresdner
- 752 Hausärzte. Gesundheitswesen 2019;81:822–30. https://doi.org/10.1055/a-0664-0470.
- 753 Hernán MA, Robins JM. Using Big Data to Emulate a Target Trial When a [59]
- 754 Randomized Trial Is Not Available: Table 1. Am J Epidemiol 2016;183:758-64.

It is made available under a CC-BY 4.0 International license .

- 755 https://doi.org/10.1093/aje/kwv254.
- 756 [60] D'Arcy M, Stürmer T, Lund JL. The importance and implications of comparator
- rsi selection in pharmacoepidemiologic research. Curr Epidemiol Rep 2018;5:272–83.
- 758 https://doi.org/10.1007/s40471-018-0155-y.
- 759 [61] Luijken K, van Eekelen R, Gardarsdottir H, Groenwold RHH, van Geloven N. Tell me
- 760 what you want, what you really really want: Estimands in observational
- pharmacoepidemiologic comparative effectiveness and safety studies. Pharmacoepidemiol
  Drug Saf 2023;32:863–72. https://doi.org/10.1002/pds.5620.
- 762 Drug Saf 2023;32:863–72. https://doi.org/10.1002/pds.5620.
- [62] European Medicines Agency. ICH E9 (R1) addendum on estimands and sensitivityanalysis in clinical trials to the guideline on statistical principles for clinical trials 2020.
- 765 [63] Burger HU, Gerlinger C, Harbron C, Koch A, Posch M, Rochon J, et al. The use of
- 766 external controls: To what extent can it currently be recommended? Pharm Stat
- 767 2021;20:1002–16. https://doi.org/10.1002/pst.2120.
- 768 [64] Nguyen VT, Engleton M, Davison M, Ravaud P, Porcher R, Boutron I. Risk of bias in 769 observational studies using routinely collected data of comparative effectiveness research: a
- 770 meta-research study. BMC Med 2021;19:279. https://doi.org/10.1186/s12916-021-02151-w.
- 771 [65] Hernán MA, Wang W, Leaf DE. Target Trial Emulation: A Framework for Causal
- 772 Inference From Observational Data. JAMA 2022;328:2446.
- 773 https://doi.org/10.1001/jama.2022.21383.
- [66] Coltin H, Pequeno P, Liu N, Tsang DS, Gupta S, Taylor MD, et al. The Burden of
- 775 Surviving Childhood Medulloblastoma: A Population-Based, Matched Cohort Study in
- 776 Ontario, Canada. J Clin Oncol Off J Am Soc Clin Oncol 2023;41:2372-81.
- 777 https://doi.org/10.1200/JCO.22.02466.
- [67] Song Q, Bates B, Shao YR, Hsu F-C, Liu F, Madhira V, et al. Risk and Outcome of
- 779 Breakthrough COVID-19 Infections in Vaccinated Patients With Cancer: Real-World
- 780 Evidence From the National COVID Cohort Collaborative. J Clin Oncol Off J Am Soc Clin
- 781 Oncol 2022;40:1414–27. https://doi.org/10.1200/JCO.21.02419.
- 782

# 783 Supplementary Material

- 784 Supplementary S1
- 785 Table S1 Search strategy

(1) In Title and Abstract		(2) Journals	(3) Time
real-world evidence <b>OR</b>		The New England journal of medicine <b>OR</b>	
Real-world data <b>OR</b> real-world <b>OR</b> RWE <b>OR</b>		The Lancet. Oncology <b>OR</b> BMJ (Clinical research ed.) <b>OR</b> JAMA <b>OR</b>	Filter:
routine data <b>OR</b>	AND	Journal of clinical oncology: official journal of the American Society of Clinical Oncology <b>OR</b>	2018 – 2023
routine care data <b>OR</b> Emulation <b>OR</b> Electronic health record		JAMA oncology <b>OR</b> Lancet (London, England)	

786 787

Table S2 Detailed Search History PubMed on October 31st 2023

#1	Search: ("The New England journal of medicine"[Journal]) OR ("BMJ (Clinical research ed.)" [Journal]) OR ("The Lancet. Oncology" [Journal]) OR ("JAMA" [Journal]) OR ("Journal of clinical oncology : official journal of the American Society of Clinical Oncology" [Journal]) OR ("JAMA oncology" (Journal]) OR ("Lancet (London, England)"[Journal])	435,802
#2	Search: "real-world evidence" [tiab] OR "Real-world data" [tiab] OR real-world[tiab] OR RWE[tiab] OR "routine data" [tiab] or "routine care data " [tiab] OR Emulation [tiab] OR "Electronic health record" [tiab]	103,854
#3	Search: #1 AND #2	387
#4	Search: #1 AND #2 Filters: from 2018-2023	227

788

# 789 Supplementary S2

790 Table S3 Glossary of terms including RWD-specific indication

Category	Definition	RWD
Confounding	Confounding appears if the intervention/exposition is associated with the outcome. Includes confounding by indication and residual confounding (unmeasured confounding). [15]	
Selection Bias	Bias introduced by the selection of the reference group. Including racial, survivor and volunteer bias. [15]	
Information Bias	Misclassification of the intervention status or outcomes, or measurement error in outcomes, can lead to information bias. [15]	
Reporting Bias	Bias due to the selection of the reported results [15]	
Coding Challenges	Heterogeneity in coding practices, also with respect to upcoding, or coding systems	x
Operationalization or Availability of Variables	Variables are not available in the EHR-system to the extend or in the form needed for research. This may lead to potential unmeasured confounding or selection bias.	X
Missing Data	Missing records within variables available in the EHR-system. E.g. not all laboratory variables will be measured at each visit because they might be irrelevant for routine care.	х
Follow-up Challenges	Handling different lengths of follow-ups, limited follow up due changes over time	

It is made available under a CC-BY 4.0 International license .

Validation & Data Quality	Challenges in validation of EHR-Data and changing data quality over time, e.g. due to ongoing digitalization.	х
Burden of Disease challenges*	Missing information due to death Heterogeneity and specialization of hospitals Calibration of algorithms	
Safety and Risk Group challenges*	Case vs. patients: a patient has multiple cases associated with them in routine clinical data. Specifying whether the study is on case- or patient-level.	Х
	Reverse p-hacking: intentionally favoring non-significant results	
	Missing information regarding the reason for therapy switch Treatment pathways heterogeneity	х
	Off-label medication use	х
Treatment Comparison	Sector boundaries and data availability: challenges in data transferability between different data sectors	х
challenges*	Uncertainty about timing of intervention	х
	Control group definition	Х
	Verifiability of inclusion and exclusion criteria	Х
	Follow up duration- specifically with regards to the lag of efficacy in drugs	
Added General Limitations	Record Linkage: the linkage of different data sources (e.g. registries, biobanks, etc.) or other hospitals/medical facilities	х
	Selection of measurements	х
	Case overlap and data overlap when using different data bases	x
	Estimator vs. Estimand: differentiation and meaning of these terms.	

791

\*Challenges that were added by the focus group discussion, Abbreviations: EHR...Electronic

#### 793 Health Records

794

#### 795 Supplementary S3

Table S4 provides a comprehensive overview of the extracted studies, including their
 characteristics and limitations described in their respective discussion section. Note,

that for some publications (indicated with an asterisk) the category could not be

- rearly assigned, especially in the case of Treatment Comparison and Safety and
- 800 Risk Group Analysis. These publications did not only compare the effectiveness of
- treatments but specifically compared the risk of adverse events between two or more
- 802 treatments [32,35,38–40,43,45].

803 All studies categorized into the Burden of Disease scenario were cohort studies

804 except for three studies [20,23,26] that were developing or validating a machine

It is made available under a CC-BY 4.0 International license .

805 learning model to predict certain endpoints using EHR data. Three studies [24.27,66] 806 examined time-to-event outcomes using Cox regression as well as Kaplan-Meier 807 estimator partly with inverse propensity weights. Prevalence and incidences were 808 analyzed in four studies [21,22,25,28]. The studies that were assigned to the 809 category Safety and Risk Group Analysis were mostly cohort studies, in addition to 810 two case-control studies and one cross-sectional cohort study [30,31]. Similar to the 811 category Burden of Disease, predominantly time-to-event outcomes were evaluated 812 using Kaplan-Meier estimation or Cox (proportional hazards) regression models 813 [32,35,36,38-40,42-44]. In contrast, many studies have used propensity score 814 methods such as matching and weighting [30,32,35,38-40,43,44] or applied the 815 concept of target trial emulation [30,35,43]. Similar to the category Safety and Risk 816 Group Analysis, most studies in the Treatment Comparison scenario examined time-817 to-event outcomes. They employed propensity score methods such as matching and 818 weighting or applied the concept of target trial emulation. In addition to that, two 819 studies used the clone method, a special form of emulating a target trial where each 820 individual is cloned into both treatment groups, censored patients according to their 821 designated treatment strategy and weighted the uncensored to avoid selection bias 822 [48,54,59].

### 823 Table S4 Overview of study characteristics and limitations

Author	Study Design	Aim of Study	Outcome	Methods	Scop e	Count ries	Limitati	ons							
	Design				C	1103	Main B	ias Categ	ories		Additiona	Additional Bias Category			
Burden of disease						1	Confo undin g	Selec tion bias	Inform ation bias	Reporti ng bias	Follow- up Challen ges	Missing Data	Coding Challen ges	Validati on & Data quality	Operatio nalization or availabilit y of variables
Beck et al. [22]	cohort study	genetic association	prevalenc e	Poisson test	multi- cente r	USA		x	x				x		
Biccler et al. [27]	cohort study	relapse risk and loss of lifetime after treatment	relapse risks, survival	logistic regression, KM estimation, Aalen- Johansen estimation	multi- natio nal	Nordi c count ries	x				x			X	
Canavan et al. [19]	cohort study	association of EOL treatment and practice-level factors	use of EOL therapy	adjusted logistic regression with random intercept	natio n- wide	USA	x	x	x	x		x			x
Chang et al. [28]	cohort study	genetic association	prevalenc e	adjusted Firth logistic regression	multi- cente r	USA		x	x	x				x	
Coltin et al. [66]	cohort study	burden of surviving disease	cumulativ e incidence of mortality	time-to-event analyses, Cox model	multi- cente r	Cana da		x			x				
Forrest et al. [23]	cohort study	disease- predictive ML	disease prediction	random forest model, model evaluation: AUROC, Sensitivity, Specificity, PPV, NPV, Brier score, adj. linear -,	natio n- wide	UK		x	x			x			

It is made available under a CC-BY 4.0 International license .

				logistic -, and Cox regression											
Haas et al. [25]	cohort study	impact and effectiveness of treatment	prevalenc e, incidence rate ratio	negative binomial regression	natio n- wide	Israel	x	x	x	x					
Kamran et al. [20]	cohort study	ML model development	mortality, treatment events	regularized logistic regression, AUROC, model calibration	multi- cente r	USA	x								x
Manz et al. [26]	cohort study	Validation of ML Algorithm	mortality	AUROC, AUPRC, scaled Brier score, logistic regression	multi- cente r	USA			x			x	x		
Vasileiou et al. [24]	cohort study	hospital admission after vaccination	hospital admission	time- dependent Cox model & Poisson regression with inverse propensity weights	natio n- wide	UK	x	x			x				
Witberg et al. [21]	cohort study	frequency and severity of disease after treatment	(cumulati ve) incidence	KM estimation	natio n- wide	Israel		x	x			x			
Safety and F	Risk Group						Confo undin g	Selec tion bias	Inform ation bias	Reporti ng bias	Follow- up Challen ges	Missing Data	Coding Challen ges	Validati on & Data quality	Operatio nalization or availabilit y of variables
Berry et al. [42]	cohort study	genetic association	incidence, prevalenc e	Cox regression, adj. logistic regression	multi- cente r	USA UK	x	x	x					x	
Chavez- MacGrego	cohort study	outcome comparison of	morality, ventilation	adj. logistic regression	multi- cente	USA	x	x							x

r et al. [41]		risk groups	, ICU stay, hospitaliz ation		r									
Chemaitell y et al. [44]	cohort studies	treatment effectiveness among children and adolescents	incidence rate, cumulativ e incidence	1:1 matching, KM estimation, Cox regression	natio n- wide	Qatar	x	x		x				
Cohen- Stavi et al. [30]	cohort study, case- control study	treatment effectiveness among children	cumulativ e incidence	target trail emulation, matching, KM estimation	multi- cente r	Israel	x		x		x			
Damrauer et al. [31]	case- control study, cross sectional study	genetic association	prevalenc e	adj. logistic regressions	multi- cente r	USA		x	x			x	x	
Deng et al. [43]*	cohort study	comparative effectiveness	time to event	target trail emulation, inverse probability of treatment weighting, generalized boosted models for PS, inverse probability of treatment weighted Kaplan-Meier method, PS- weighted Cox regression	natio n- wide	USA	x	X	X		x	X		X
Filion et al. [32]*	cohort study	adverse event association	major adverse events	time conditional PS using conditional logistic regression, 1:1	multi- cente r	Cana da UK	x	×	x	X	X			x

It is made available under a CC-BY 4.0 International license .

medRxiv preprint doi: https://doi.org/10.1101/2024.09.05.24313049; this version posted December 13, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

				matching, Cox regression											
Forrest et al. [33]	cohort study	disease risk associated with gene variants	risk difference between prevalenc e	2-sided Fisher's exact tests	multi- cente r	USA UK		x	x				x		
Harstad et al. [45]*	observatio nal study	treatment effectiveness	frequency , relative risk of Adverse Effects	logistic and Cox regression	multi- cente r	USA	x	x			x			x	
Li et al. [34]	cohort study	adverse event association	incidence rate	descriptive analyses	multi- natio nal	Austr alia Franc e Germ any Japan Nethe rlands Spain UK US			x	x		x		x	
Lyu et al. [35]*	cohort study	comparative effectiveness	incidence	target trail emulation, PS- matching, Cox regression	natio n- wide	UK	x		x		x				
Martin et al. [36]	cohort study	therapy evaluation	time-to- next- treatment, overall survival	KM, Cox regression	natio n- wide	USA	x		x			x			x
Seymour et al. [37]	cohort study	phenotype derivation	phenotyp e frequency , mortality	Multiple imputation, k- means clustering	single - cente r	USA		x	x			x			
Song et al. [67]	cohort study	comparative effectiveness	disease risk	adj. logistic regression	natio n- wide	USA	x			x					
Suchard et al. [39]*	cohort study	comparative effectiveness	relative risk	PS model, matching, Cox regression,	multi- natio nal	USA South Korea	x	x	x	x					

Vinogrado va et al.[40]* You et al. [38]*	cohort study cohort study	treatment association treatment association	hospital admission or death net adverse clinical events	meta analysis PS, Cox regression PS-matching, Cox regression	natio n- wide multi- cente r	Japan Germ any UK South Korea USA	X X		X X	x x	Fallow	Ministra	Oction	X	X X	
Treatment C	Comparison						Confo undin g	Selec tion bias	Inform ation bias	Reporti ng bias	Follow- up Challen ges	Missing Data	Coding Challen ges	Validati on & Data quality	Operatio nalization or availabilit y of variables	nade
Andersson et al. [52]	cohort study	comparative effectiveness	hospital admission , death	target trail emulation, PS- matching, inverse probability of treatment weights, KM	multi- natio nal	Nordi c count ries	x	X	x							available under a CC-BY 4.0
Deputy et al. [53]	case- control study	vaccine effectiveness	associatio n between vaccinatio n status and case patient or control patient status	matching, conditional logistic regression	natio n- wide	USA	x	x	x							CC-BY 4.0 International license .
Kim et al. [47]	cohort study	treatment effectiveness	time to cardiovas cular events	PS-matching, stratified Cox regression	natio n- wide	South Korea	x	x	x	x						
Mahévas et al. [49]	case- control study	treatment effectiveness	survival	inverse probability of treatment weighting, Cox	multi- cente r	Franc e	x	x							x	

				regression, KM, multiple imputation												
Marafino et al. [57]	cohort study	intervention association	mortality, readmissi on	target-trail emulation, generalized linear mixed effects models, difference-in- difference analysis	multi- cente r	USA	x	x					x			SI 11
Rentsch et al. [50]	cohort study	early treatment association	mortality	inverse probability of treatment weighted KM, Cox regression	natio n- wide	USA	x	x	x			x		x	x	made available i
Wang et al. [51]	cohort study	RCT comparison	time to event	target trail emulation, PS matching, Cox regression	natio n- wide	USA	x	x		x	x					under a CC
Wong et al. [56]	cohort study, case- control study	comparative effectiveness	mortality, hospital admission , progressi on	propensity score matching, Cox regression, conditional logistic regression	territo ry- wide	Hong Kong	x	x	x			x				It is made available under a CC-BY 4.0 International license
Xie et al. [48]	cohort study	treatment association	relative risk, event rate, absolute risk reduction: hospital admission , death	target trail emulation, clone method, inverse probability of censoring weight	natio n- wide	USA	x		x							al license .
Xie et al. [54]	cohort study	treatment effectiveness	relative risk, event rate,	target trail emulation, inverse probability	natio n- wide	USA	x	x	x							

			absolute risk reduction: hospital admission , death	weighting, clone method, weighted KM								
Zheng et al. [55]	cohort study	comparative effectiveness	hospital admission , death	Cox regression, PS- weighting	natio n- wide	UK	x	x	x			x

824

825 Abbreviation: KM... Kaplan-Meier, PS... Propensity Score, EOL... End-of-Life, ICU... Intensive Care Unit, ML... Machine Learning,

826 AUROC... Area under the receiver operating curve, AUPRC... Area under the precision-recall curve

\* This indicates publications that were not uniquely categorizable into the main scenarios. Specifically, they did not only compare the

828 effectiveness of treatments but compared the risk of adverse events between two or more treatments

It is made available under a CC-BY 4.0 International license